鸡肠道菌群和短链脂肪酸相互关系的研究进展

肠道是动物机体重要的消化和营养吸收器官。肠道菌群决定肠道健康,进而影响机体健康。近来关于肠道菌群的研究越来越多,且肠道菌群酵解底物产生的短链脂肪酸也备受人们关注。短链脂肪酸主要包括乙酸、丙酸、丁酸等及其盐类。在对肠道功效方面,短链脂肪酸发挥着重要作用,如氧化供能、维持水电解质平衡、调节免疫、抗病原微生物及抗炎、调节肠道菌群平衡、改善肠道功能等。因此,本文根据近年来国内外相关研究报道,综述了鸡肠道不同种类、含量的菌群对短链脂肪酸来源和吸收的影响;不同种类、含量和制剂形态的短链脂肪酸对肠道菌群影响的研究进展,为更好地了解鸡肠道菌群和短链脂肪酸的相互关系和提高禽类养殖水平提供理论指导。     

运动、肠道菌群代谢物——短链脂肪酸与骨骼肌代谢调控

寄生于人体的肠道菌群是一个高度动态化和个体化的复杂生态系统,受遗传、环境、饮食、年龄和运动等因素的影响,并通过其产生的代谢物与机体众多组织器官产生广泛的应答效应。短链脂肪酸(short chain fatty acid, SCFA)主要是由位于盲肠和结肠内的菌群以膳食纤维为底物发酵产生,其被吸收进入肠系膜上下静脉,随后汇入门静脉至肝。部分短链脂肪酸被肝作为糖异生和脂质合成的底物,剩余的短链脂肪酸以游离脂肪酸的形式经肝静脉进入外周循环。研究发现,运动可使产生SCFA的肠道菌群组分的丰度提高和参与调控SCFA生成的相关基因表达增加,使肠道中短链脂肪酸含量增加。由短链脂肪酸刺激结肠内分泌细胞合成分泌的胰高血糖素样肽1(glucagon like peptide-1, GLP-1)可促使胰岛B细胞合成分泌胰岛素,进而调节骨骼肌的葡萄糖摄取与糖原合成。此外,短链脂肪酸通过提高骨骼肌胰岛素受体底物1(insulin receptor substrate 1,IRS1)基因转录起始位点附近的组蛋白乙酰化水平,增强骨骼肌的胰岛素敏感性。同时,短链脂肪酸通过激活腺苷酸活化蛋白质激酶(AMP-activated protein kinase, AMPK)促进骨骼肌的脂肪酸摄取、脂肪分解和线粒体生物发生,抑制脂肪合成。本文就肠道菌群代谢物——短链脂肪酸概述、运动对产生短链脂肪酸的肠道菌群的影响和运动介导肠道菌群代谢物——短链脂肪酸对骨骼肌代谢调控机制的最新研究进展进行综述,为骨骼肌运动适应的新机制研究提供理论依据。     

人体肠道菌群与高血压的研究进展

高血压是一种以血压升高为特征的疾病。除少数继发性高血压外,大多数高血压发生的病因至今尚未明确。近年来,越来越多的研究表明高血压的发生机制与肠道菌群有关。通过对最新的研究进行分析,发现膳食纤维、高盐摄入等因素可刺激肠道菌群,进而对高血压产生不同的影响。短链脂肪酸作为肠道菌群的发酵产物,是膳食纤维具有降血压作用的主要原因。高盐摄入导致高血压,是因为肠道菌群引起了免疫系统的改变。另外,高血压的形成也与肠道致病微生物的异质性炎症反应有关。此综述希望能为高血压的控制与防治提供新的科学依据与研究思路。     

肠道菌群在代谢手术改善肥胖代谢性疾病中的研究进展

肥胖不仅是体内脂肪细胞的增加,而且是机体代谢状态的异常改变,导致肥胖患者出现2型糖尿病、非酒精性脂肪性肝病、心血管疾病和多囊卵巢综合征等代谢紊乱性疾病。代谢手术在减重的同时,能够治疗和缓解由肥胖导致的相关疾病。对代谢手术改善肥胖及其合并症的机制研究发现,肠道微生物在术后显著改变,这促使肠道菌群及其代谢产物（短链脂肪酸和胆汁酸）等成为代谢手术改善代谢效应机制研究的热点。随着粪菌移植和口服益生菌治疗肥胖及其合并症的报道,进一步验证了肠道菌群在改善肥胖及其相关并发症中发挥有益作用。本综述将总结肠道菌群在代谢手术领域中的最新研究进展。     

老年小鼠肠道短链脂肪酸含量和菌群特征关联性探究

随着社会经济的发展,我国人口老龄化日益严重,衰老这个永恒的问题又一次引起人们的关注.肠道菌群失衡是衰老发生发展的关键因素,而短链脂肪酸(short chain fatty acids,SCFAs)是介导菌群影响机体的主要方式之一.研究衰老、肠道菌群及SCFAs三者之间的关系,能够为临床通过干预肠道菌群影响SCFAs含量...     

小鼠肠道菌群代谢产物与糖尿病的相关性研究

目的研究糖尿病小鼠粪便中肠道菌群代谢产物与血糖之间的相关性,探讨肠道菌群与糖尿病之间的关系。方法采用高脂饮料喂养加腹腔注射链脲佐菌素(STZ)的方法建立糖尿病小鼠模型;将实验动物随机分为正常组、高脂组、糖尿病组及模型给药组,连续给药5周后,采血测血糖血脂,同步收集动物粪便,测粪便中短链脂肪酸(Short-chain fatty acids,SCFA)及D-乳酸。SCFA的检测使用气相色谱法,D-乳酸的检测使用紫外酶促法。结果糖尿病组小鼠粪便中乙酸、丙酸和正丁酸含量明显低于正常组及高脂组(P<0.01),D-乳酸含量明显高于正常组及高脂组(P<0.01);给药组乙酸、丙酸和正丁酸含量明显高于糖尿病组(P<0.01),D-乳酸含量明显低于糖尿病组(P<0.01)。给药组丙酸、正丁酸的含量与正常组间差异无统计学意义(P>0.05),但乙酸的含量仍低于正常组(P<0.01),D-乳酸的含量仍高于正常组(P<0.01)。结论糖尿病小鼠粪便中的肠道菌群代谢产物与血糖之间存在着密切的关系,代谢产物的差异性,提示肠道菌群的差异性,反映出糖尿病小鼠存在肠道菌群紊乱。     

基于肠道菌群和短链脂肪酸代谢探讨不同饮食条件下高脂血症大鼠发病机制

目的 本研究拟对比两种不同高脂饮食方式诱导的高脂血症大鼠肠道菌群变化与短链脂肪酸代谢特征,以宿主-肠道菌群-代谢角度探讨高脂血症可能的微观机制。方法 SPF级SD大鼠分为：正常饮食组(CG组):饲喂大鼠维持饲料;高脂饮食组(HFD1组):每天足量饲喂高脂饲料;限饲高脂饮食组(HFD2组):每天限量饲喂高脂饲料80 g,不限量饲喂维持饲料。8周后检测血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)水平;苏木精-伊红(HE)染色观察大鼠肝组织和肾周脂肪病理学变化;取结肠内容物进行16S rDNA高通量测序,观察肠道菌群结构与功能的变化,并检测结肠内容物中短链脂肪酸的含量。结果 与CG组相比,HFD1组和HFD2组大鼠摄食量下降,体重升高;血清中TC、TG、LDL-C均显著升高;肝组织发生明显脂肪变性,肾周脂肪出现炎性病变;高脂干预后大鼠肠道菌群相对丰度显著变化,其中乳杆菌属相对丰度明显降低,菌群结构和功能变化明显,总短链脂肪酸、乙酸、丁酸、异丁酸下降显著。结论 两种高脂饮食方式均能引起大鼠高脂血症,且发病机制基本一致,均与脂质代谢以...     

肠道菌群与宿主关系解析及肠道菌群调控/合成研究进展

肠道菌群和宿主健康之间有着密切的关系,其与宿主之间存在着复杂的相互作用,如菌群及其代谢产物与免疫系统的互作、脑-肠轴、肺-肠轴等.肠道菌群紊乱与多种疾病的发生和发展存在相关性,且部分微生物菌株与一些疾病的发生存在着因果关系.肠道菌群还会影响药物代谢,个体差异的肠道菌群使得不同个体对于同种药物的代谢具有很大差别;解析个体肠道菌群的状态及其与宿主之间的关系是实施个性化精准诊疗的重要环节.肠道菌群具有可塑性,通过饮食调控、益生菌/益生元/合生元补充、粪菌移植等干预手段可以使肠道菌群处于健康状态,应用肠道菌群编辑和合成肠道微生物组等新技术调控、合成肠道菌群的研究已有报道.目前,利用合成生物学等方法调控肠道菌群已成为改善和治疗疾病的有效方法之一.本文综述了肠道菌群与人体等宿主的相互作用、肠道菌群与部分疾病的相关性和因果性,以及通过肠道菌群调控改善人体健康状态的策略,展望了微生物组学和合成生物学在肠道菌群调控与合成方面的应用.     

缺铁性贫血中肠道菌群作用的研究进展

缺铁性贫血是临床最常见的贫血类型之一,已知缺铁性贫血会导致机体免疫力下降,影响心血管系统,对儿童和青少年的智力发育造成损害。然而越来越多的学者发现缺铁还会引起肠道菌群结构发生改变,影响肠道菌群的代谢。短链脂肪酸作为肠道菌群代谢的主要产物,受铁的制约最大。短链脂肪酸对机体肠道健康起着至关重要的作用,因此缺铁是有害的。另外临床工作中发现益生菌联合铁剂治疗缺铁性贫血,疗效更显著;铁剂联合抗菌药物对细菌相关疾病的治疗效果大大提高,说明铁与肠道菌群关系密切。本文就缺铁性贫血与肠道菌群关系的研究进展作一综述。     

肠道菌群代谢产物及酶对骨代谢的影响机制初探

骨质疏松症是一种常见的代谢性骨病,其发病并非是由单一因素引起,而是由多种因素所致。人们生活水平和医疗条件的提高使人们寿命延长导致老龄化现象,对应的骨质疏松症的发病率也处于上升趋势。骨质疏松在全球范围都是一个值得关注的健康问题。骨质疏松的治疗一直以基础治疗为主,包括生活方式干预和基础营养素补充,药物治疗,还有治疗后期的康复训练。但近年来愈来愈多的研究表明骨质疏松症和肠道菌群之间密切相关,因而肠道菌群已成为抗骨质疏松的一个新靶点。本文结合国内外相关文献就骨质疏松是如何受肠道菌群代谢产物及酶的影响作一综述。     

The role of short-chain fatty acids in the interplay between diet,gut microbiota,and host energy metabolism

Short-chain fatty acids (SCFAs), the end products of fermentation of dietary fibers by the anaerobic intestinal microbiota, have been shown to exert multiple beneficial effects on mammalian energy metabolism. The mechanisms underlying these effects are the subject of intensive research and encompass the complex interplay between diet, gut microbiota, and host energy metabolism. This review summarizes the role of SCFAs in host energy metabolism, starting from the production by the gut microbiota to the uptake by the host and ending with the effects on host metabolism. There are interesting leads on the underlying molecular mechanisms, but there are also many apparently contradictory results. A coherent understanding of the multilevel network in which SCFAs exert their effects is hampered by the lack of quantitative data on actual fluxes of SCFAs and metabolic processes regulated by SCFAs. In this review we address questions that, when answered, will bring us a great step forward in elucidating the role of SCFAs in mammalian energy metabolism.     

肠道菌群改变与结核分枝杆菌感染相互作用的研究进展

人体内肠道菌群数量庞大,参与机体物质代谢以及免疫应答反应,成为目前众多研究的热点.肠道菌群对于维持呼吸系统稳态,特别是肺部的稳态发挥着重要作用.目前越来越多的结果证明肠道菌群对机体免疫系统具有诱导和调节作用,这种免疫反应的改变对于结核病的发病和治疗有着深远意义.本文梳理了近年来国内外发表的肠道菌群与结核病相关的文献,讨...     

Dietary fibers as emerging nutritional factors against diabetes: focus on the involvement of gut microbiota

Diabetes mellitus (DM) increases the risk of cardiovascular diseases and other secondary complications, such as nephropathy, neuropathy, retinopathy, etc. The important risk factors for the pathogenesis of DM are aging, family history, sedentary lifestyle, unhealthy dietary habits, and obesity. Evidence from epidemiological studies also indicates that DM is characterized by specific alterations in the human gut microbiota (GM). GM transplantation in rodents and humans revealed that a specific GM constituent can be the cause and not just the consequence of the DM condition and complications. These findings suggest a potential role of GM in human health, disease prevention, and treatment. Dietary intervention studies using dietary fibers (DFs) suggested that modulation of the GM can suppress the metabolic risk markers in humans. However, a causal role of GM in such studies remains unexplored. Long-term follow-up studies disclosed that the diet rich in insoluble and non-viscous fibers are responsible for DF-mediated antidiabetic activities, while soluble and viscous fibers have little influence on DM despite having a profound impact on glycemia. However, general conclusions cannot be drawn simply based on these findings. Long-term follow-up studies are urgently required in this area to explore the therapeutic potential of different DFs in treating DM and to delineate the exact role of GM involvement. Here we review and discuss the signature of GM during DM, antidiabetic activity of metformin via GM modulation, DFs from different sources and their antidiabetic activity, and the possible role of GM involvement.     

Characterization of gut microbiota and short-chain fatty acid in breastfed infants with or without breast milk jaundice

This study aims to investigate the gut microbiota and metabolites in breastfed infants with breast milk jaundice (BMJ) using gut microbiome–metabolomics. Breastfed newborns diagnosed with BMJ and those without BMJ (control group) were enrolled. Faecal samples were collected from the participants and subjected to high-throughput sequencing of the 16s rDNA V3 and V4 regions of the gut flora and metabolomics of short-chain fatty acids (SCFAs). Proteobacteria, Fimicutes and Actinobacteria were the main bacteria at the phylum level. Eshcerichia-Shigella and Enterobacteriacea were the main bacteria at the genus level. The difference between the two groups was compared. Compared to the control group, the amount of Streptococcus was significantly increased while the amount of Enterococcus was significantly decreased in the faeces from infants with BMJ. Functional prediction analysis of 16S found that biosynthesis of penicillin and cephalosporin significantly increased in the BMJ group. Gas chromatography–mass spectrometry detection of SCFAs revealed that levels of acetic acid and propionic acid were significantly lower in the BMJ group than in the control group. The reduced levels of acetic acid and propionic acid may be related to the increase in Streptococcus and decrease in Enterococcus, both of which may contribute to BMJ.     

短链脂肪酸调控骨代谢的作用及机制的研究进展

肠道菌群紊乱可导致宿主病理性骨质流失,其通过产生的代谢物从肠道扩散到体循环对骨代谢发挥重要的调控作用。短链脂肪酸（Short Chain Fatty Acids,SCFAs）是肠道细菌产生的代谢物家族中最受关注的代谢产物,近年来研究表明,SCFAs在骨代谢相关疾病的发生发展中具有重要调节作用。本文就其在骨骼系统中的作用、调节骨组织中细胞的机制及作为靶点防治骨代谢疾病骨质疏松的研究进行综述,并为此新兴且具有前景的研究领域在未来的基础研究和转化研究提供展望。     

Structural resilience of the gut microbiota in adult mice under high-fat dietary perturbations

Disruption of the gut microbiota by high-fat diet (HFD) has been implicated in the development of obesity. It remains to be elucidated whether the HFD-induced shifts occur at the phylum level or whether they can be attributed to specific phylotypes; additionally, it is unclear to what extent the changes are reversible under normal chow (NC) feeding. One group (diet-induced obesity, DIO) of adult C57BL/6J mice was fed a HFD for 12 weeks until significant obesity and insulin resistance were observed, and then these mice were switched to NC feeding for 10 weeks. Upon switching to NC feeding, the metabolic deteriorations observed during HFD consumption were significantly alleviated. The second group (control, CHO) remained healthy under continuous NC feeding. UniFrac analysis of bar-coded pyrosequencing data showed continued structural segregation of DIO from CHO on HFD. At 4 weeks after switching back to NC, the gut microbiota in the DIO group had already moved back to the CHO space, and continued to progress along the same age trajectory and completely converged with CHO after 10 weeks. Redundancy analysis identified 77 key phylotypes responding to the dietary perturbations. HFD-induced shifts of these phylotypes all reverted to CHO levels over time. Some of these phylotypes exhibited robust age-related changes despite the dramatic abundance variations in response to dietary alternations. These findings suggest that HFD-induced structural changes of the gut microbiota can be attributed to reversible elevation or diminution of specific phylotypes, indicating the significant structural resilience of the gut microbiota of adult mice to dietary perturbations.     

Effects of oral sialic acid on gut development,liver function and gut microbiota in mice

Sialic acid (N-acetylneuraminic acid), a 9-carbon monosaccharide, has been widely studied in immunology, oncology and neurology. However, the effects of sialic acid on organ and intestinal development, liver function and gut microbiota were rarely studied. In this study, we found that oral sialic acid tended to increase the relative weight of liver and decreased the serum aspartate aminotransferase (GPT) activity. In addition, sialic acid treatment markedly reduced gut villus length, depth, the ratio of villus length/depth (L/D), areas, width and the number of goblet cells. Furthermore, gut microbes were changed in response to oral sialic acid, such as Staphylococcus lentus, Corynebacterium stationis, Corynebacterium urealyticum, Jeotgalibaca sp_PTS2502, Ignatzschineria indica, Sporosarcina pasteurii, Sporosarcina sp_HW10C2, Facklamia tabacinasalis, Oblitimonas alkaliphila, Erysipelatoclostridium ramosum, Blautia sp_YL58, Bacteroids thetaiotaomicron, Morganella morganii, Clostridioides difficile, Helicobacter tryphlonius, Clostridium sp_Clone47, Alistipes finegoldii, [pseudomonas]_geniculata and Pseudomonas parafulva at the species level. In conclusion, oral sialic acid altered the intestinal pathological state and microbial compositions, and the effect of sialic acid on host health should be further studied.     

Astragaloside IV alleviates mouse slow transit constipation by modulating gut microbiota profile and promoting butyric acid generation

Gut microbiota and short‐chain fatty acids (SCFAs) are associated with the development of various human diseases. In this study, we examined the role of astragaloside IV in modulating mouse gut microbiota structure and the generation of SCFAs, as well as in slow transit constipation (STC). An STC model was established by treating mice with loperamide, in which the therapeutic effects of astragaloside IV were evaluated. The microbiota community structure and SCFA content were analysed by 16S rRNA gene sequencing and gas chromatography‐mass spectrometry, respectively. The influence of butyrate on STC was assessed using a mouse model and Cajal cells (ICC). Astragaloside IV promoted defecation, improved intestinal mobility, suppressed ICC loss and alleviated colonic lesions in STC mice. Alterations in gut microbiota community structure in STC mice, such as decreased Lactobacillus reuteri diversity, were improved following astragaloside IV treatment. Moreover, astragaloside IV up‐regulated butyric acid and valeric acid, but decreased isovaleric acid, in STC mouse stools. Butyrate promoted defecation, improved intestinal mobility, and enhanced ICC proliferation by regulating the AKT–NF‐κB signalling pathway. Astragaloside IV promoted intestinal transit in STC mice and inhibited ICC loss by regulating the gut microbiota community structure and generating butyric acid.